Drug Development/R&D

How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines.

In this OHE lunchtime seminar, Prof Heidi Williams of MIT will present the results of a recent paper using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera to investigate how Celera's gene-level IP influenced subsequent scientific research and product development.

To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.

OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts from industry, academia and government. The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions about cost-effectiveness.

This post reviews selected external OHE activities and publications from the past three months.

What will drug development look like in 10 years’ time? How will regulatory policies and the global political and social environment shape it? How might policy choices affect the rate and direction of R&D? Which initiatives might help ensure that the UK will continue to host important R&D? These and other critical questions will be addressed at OHE’s 50th Anniversary conference.

What will drug development look like in 10 years’ time? How will regulatory policies and the global political and social environment shape it? How might policy choices affect the rate and direction of R&D? Which initiatives might help ensure that the UK will continue to host important R&D? These and other critical questions will be addressed at OHE’s 50th Anniversary conference.

OHE has added important panelists and speakers to fill out the conference programme for The Challenges and Economics of Drug Development in 2022, scheduled for 8 October in London. The conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development.

Throughout its 50-year history, OHE has been a leader in contributing to the understanding of important trends in health care and in the life science industries, in the UK and outside. This conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development.

In response to the R&D productivity crisis affecting the pharmaceutical industry, "big pharma" is seeking to source therapeutics from small and medium sized enterprises (SMEs). In this seminar, Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that have played a part in projects reaching late stage clinical trials.

Pages

Subscribe to RSS - Drug Development/R&D